Skip to main content
Clinical Trials/NCT02698657
NCT02698657
Completed
Phase 1

A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Astellas Pharma Global Development, Inc.13 sites in 2 countries30 target enrollmentFebruary 23, 2016

Overview

Phase
Phase 1
Intervention
ASP5094
Conditions
Rheumatoid Arthritis (RA)
Sponsor
Astellas Pharma Global Development, Inc.
Enrollment
30
Locations
13
Primary Endpoint
Maximum Concentration (Cmax) of ASP5094
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of multiple ascending intravenous doses of ASP5094 in male and female subjects with rheumatoid arthritis (RA) on methotrexate (MTX).

Registry
clinicaltrials.gov
Start Date
February 23, 2016
End Date
September 7, 2017
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject has a body mass index (BMI) of ≤ 35 kg/m2, inclusive, and must weigh at least 50 kg at screening.
  • Subject has absolute neutrophil count within normal limits at screening. The assessment may be repeated once during screening.
  • Subject has RA that was diagnosed according to the 1987 revised criteria of the American College of Rheumatology (ACR) ≥ 6 months prior to screening.
  • Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class I, II or III at screening.
  • Subject MUST be on concomitant MTX:
  • for ≥ 3 months prior to day 1, and
  • at a stable dose (10 25 mg/week) for ≥ 28 days prior to day 1 and throughout the study.
  • Subject's other medications taken for the treatment of RA at the time of screening must meet the noted stability requirements and remain on a stable regimen, as follows:
  • Nonsteroidal antiinflammatory drugs (NSAIDs), selective cyclooxygenase-2 (COX- 2) inhibitors, oral corticosteroids (≤ 10 mg of prednisone, or equivalent, daily) or low dose opioids (≤ 30 mg of oral morphine, or equivalent, daily) must be stable for ≥ 28 days prior to screening,
  • Hydroxychloroquine (Plaquenil®) and sulfasalazine (e.g., Azulfidine®) must have started ≥ 2 months, and be stable for ≥ 28 days, prior to day

Exclusion Criteria

  • Subject has an ongoing clinically significant systemic disease such as uncompensated heart failure, uncontrolled diabetes mellitus, severe hepatic failure, severe pulmonary disease or inflammatory bowel disease.
  • Subject has a history of any malignancy in the past 5 years, except for adequately-treated, nonmelanoma skin cancer and adequately-treated in-situ cervical cancer.
  • Subject has a history of severe allergic or anaphylactic reactions to drugs.
  • Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/ substance abuse within past 6 months prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).
  • Subject has an ongoing infection or has had an infection requiring intravenous antibiotics within 1 month prior to day
  • Subject has a known history of a positive test for human immunodeficiency virus (HIV) antibody.
  • Subject has a past history of serious opportunistic infection.
  • Subject has a positive QuantiFERON-TB Gold test within 90 days of, or at screening, and has not completed an adequate course of antimicrobial therapy per Centers for Disease Control or local guidelines.
  • Subject's laboratory test results at screening or prior to study drug dosing on day 1:
  • Outside the normal limits and considered by the investigator to be clinically significant with regard to the remaining per-protocol laboratory tests, and/or

Arms & Interventions

ASP5094 Dose Escalation

Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.

Intervention: ASP5094

Placebo Dose Escalation

Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.

Intervention: Placebo

Outcomes

Primary Outcomes

Maximum Concentration (Cmax) of ASP5094

Time Frame: Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose

Change from Baseline in Peripheral Lymphocyte Subsets: CD3/Lymphocytes

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD8/Lymphocytes

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Time to maximum concentration (tmax) of ASP5094

Time Frame: Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose

Change from Baseline in Total Lymphocyte Counts

Time Frame: Baseline and days 29, 57, 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD19/Lymphocytes

Time Frame: Baseline and days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD4

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Number of Participants with Anti-ASP5094 Antibody Formation

Time Frame: Days 1 (predose), 29 (predose), 57 (predose), 71, 85, 113 and 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD19

Time Frame: Baseline and days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD3

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD4/Lymphocytes

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: CD8

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: Granulocytes/Leukocytes

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Change from Baseline in Peripheral Lymphocyte Subsets: Granulocytes

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Number of Participants with Treatment-Emergent Adverse Events

Time Frame: From first dose of study drug up to end of study (up to 141 days)

A treatment-emergent adverse event (TEAE) is defined as a newly occurring or worsening adverse event (AE) observed after starting administration of study drug up until the end of study visit, inclusive. This includes abnormal laboratory tests, vital signs or electrocardiogram data that are defined as AEs if the abnormality induces clinical signs or symptoms, requires active intervention, interruption or discontinuation of study drug or is clinically significant in the investigator's opinion. A serious AE (SAE) is defined as an AE with an outcome that results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly, or birth defect or requires inpatient hospitalization or leads to prolongation of hospitalization.

Change from Baseline in Peripheral Lymphocyte Subsets: Natural Killer Cell Subset/Lymphocytes

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Concentration immediately prior to dosing at multiple dosing (Ctrough) for ASP5094

Time Frame: Predose on days 29, 57, and 85

Change from Baseline in Peripheral Lymphocyte Subsets: Natural Killer Cells

Time Frame: Baseline and Days 29 (predose), 57 (predose), 85, 113, 141

Area under the concentration-time curve from the time of dosing on day 1 to the end of the 4-week dosing interval for ASP5094 (AUC)

Time Frame: Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose

Accumulation ratio calculated using the area under the concentration-time curve (R3ac[AUC]) for ASP5094

Time Frame: Day 57 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose

Accumulation ratio calculated using the maximum concentration (R3ac[Cmax]) for ASP5094

Time Frame: Day 57 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose

Secondary Outcomes

  • Total clearance after intravenous dosing (CL)(Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose)
  • Volume of distribution after intravenous dosing during the terminal elimination phase (VzF)(Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose)
  • Terminal elimination half-life (t1/2)(Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose)
  • Percentage of Fluctuation(Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose)

Study Sites (13)

Loading locations...

Similar Trials